| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
CTX-0294885 targets a broad range of kinases. It inhibits FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 with IC50 values of 4, 1, 3, 28, and other values. It also targets BRD4. It is a broad-spectrum kinase inhibitor.
|
|---|---|
| ln Vitro |
CTX-0294885 is a kinase capture tool in large-scale kinome profiling experiments, with 185 kinases identified as total protein, and 179 identified from TiO2 enrichment for phosphopeptides in MDA-MB-231 cells (by quantitative MS)[1].
CTX-0294885 captures all members of the AKT family that is not identified from previous studies using other kinase capture reagents[1].CTX-0294885 is a kinase capture tool in large-scale kinome profiling experiments, with 185 kinases identified as total protein, and 179 identified from TiO2 enrichment for phosphopeptides in MDA-MB-231 cells (by quantitative MS)[1].
CTX-0294885 is a broad-spectrum kinase inhibitor. It inhibits FAK, FLT3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 with IC50 values of 4, 1, 3, 28, and other values. It can capture 235 kinases from MDA-MB-231 cells. |
| ln Vivo |
CTX-0294885 is used as a kinase capture reagent for proteomics analysis. It is a powerful reagent for analysis of kinome signaling networks. It can be used in research on inflammation, diabetes, and cancer.
|
| Enzyme Assay |
CTX-0294885 is evaluated in cell-free kinase assays using a broad panel of purified kinases. The compound is incubated with each kinase, ATP, and a substrate, and the inhibition of kinase activity is measured. IC50 values are determined to quantify the potency of inhibition against each kinase.
|
| Cell Assay |
CTX-0294885 is assessed in cell-based assays using MDA-MB-231 cells and other cell lines. Cells are treated with CTX-0294885, and kinase activity is assessed by measuring phosphorylation of downstream targets. The compound's ability to capture kinases from cell lysates is evaluated using Sepharose-supported reagent.
|
| Animal Protocol |
CTX-0294885 is used in animal models as a kinase capture reagent for proteomics analysis. However, specific animal study protocols are not extensively documented. The compound is primarily used as a research tool.
|
| ADME/Pharmacokinetics |
CTX-0294885 has a molecular weight of 437.93 and a molecular formula of C22H24ClN7O. It has a CAS number of 1439934-41-4. The compound is soluble in DMSO. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for CTX-0294885. The compound is for research use only and is not intended for human therapeutic use. It is a broad-spectrum kinase inhibitor.
|
| References | |
| Additional Infomation |
CTX-0294885 is a novel broad-spectrum kinase inhibitor. It is a bisanilino pyrimidine. It is used as a kinase capture reagent. It is not approved for clinical use.
|
| Molecular Formula |
C22H24CLN7O
|
|---|---|
| Molecular Weight |
437.93
|
| Exact Mass |
437.173
|
| Elemental Analysis |
C, 60.34; H, 5.52; Cl, 8.10; N, 22.39; O, 3.65
|
| CAS # |
1439934-41-4
|
| Related CAS # |
CTX-0294885 hydrochloride
|
| PubChem CID |
71558939
|
| Appearance |
white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.674
|
| LogP |
2.22
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
31
|
| Complexity |
568
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=C([H])N=C(N=C1N([H])C1=C([H])C([H])=C([H])C([H])=C1C(N([H])C([H])([H])[H])=O)N([H])C1C([H])=C([H])C(=C([H])C=1[H])N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H]
|
| InChi Key |
FCLOIQHNUARDSR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H24ClN7O/c1-24-21(31)17-4-2-3-5-19(17)28-20-18(23)14-26-22(29-20)27-15-6-8-16(9-7-15)30-12-10-25-11-13-30/h2-9,14,25H,10-13H2,1H3,(H,24,31)(H2,26,27,28,29)
|
| Chemical Name |
2-[[5-chloro-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]-N-methylbenzamide
|
| Synonyms |
CTX0294885 CTX 0294885 CTX-0294885
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥100 mg/mL (~228.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2835 mL | 11.4173 mL | 22.8347 mL | |
| 5 mM | 0.4567 mL | 2.2835 mL | 4.5669 mL | |
| 10 mM | 0.2283 mL | 1.1417 mL | 2.2835 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
